Association of TNF-α Polymorphism with Prediction of Response to TNF Blockers in Spondyloarthritis and Inflammatory Bowel Disease: A Meta-Analysis

• Rudwaleit M , HöhlerT. Cytokine gene polymorphisms relevant for the spondyloarthropathies. Curr. Opin. Rheumatol.13(4), 250–254 (2001).
   PubMed Web of Science ®Google Scholar
• Romero-Sánchez C , RobinsonWH, TomookaBH et al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin. Rheumatol. 27(11), 1429–1435 (2008).
   PubMed Web of Science ®Google Scholar
• Sousa E , Caetano-LopesJ, PintoP et al. Ankylosing spondylitis susceptibility and severity – contribution of TNF gene promoter polymorphisms at positions -238 and -308. Ann. N.Y. Acad. Sci. 1173, 581–588 (2009).
   PubMed Web of Science ®Google Scholar
• Dougados M . Current therapy for seronegative arthritides (spondyloarthritis). Bull. NYU. Hosp. Jt Dis.69(3), 250–252 (2011).
   PubMedGoogle Scholar
• Rodgers M , EpsteinD, BojkeL et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol. Assess 15(10), i–xxi, 1–329 (2011).
   PubMed Web of Science ®Google Scholar
• Smolen JS , EmeryP. Infliximab: 12 years of experience. Arthritis Res. Ther.13(Suppl. 1), S2 (2011).
   PubMed Web of Science ®Google Scholar
• Barr A , KeatA. Spondyloarthritides: evolving therapies. Arthritis Res. Ther.12(6), 221 (2010).
   PubMedGoogle Scholar
• Hébert HL , AliFR, BowesJ et al. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br. J. Dermatol. 166(3), 474–482 (2012).
   PubMed Web of Science ®Google Scholar
• Chung WT , ChoeJY, JangWC et al. Polymorphisms of tumor necrosis factor-α promoter region for susceptibility to HLA-B27-positive ankylosing spondylitis in Korean population. Rheumatol. Int. 31(9), 1167–1175 (2011).
   PubMed Web of Science ®Google Scholar
• Lee YH , SongGG. Lack of association of TNF-α promoter polymorphisms with ankylosing spondylitis: a meta-analysis. Rheumatology (Oxf.)48(11), 1359–1362 (2009).
   PubMed Web of Science ®Google Scholar
• Romero-Sánchez C , LondoñoJ, DelgadoG et al. Association of tumor necrosis factor α-308 promoter polymorphism with spondyloarthritides patients in Colombia. Rheumatol. Int. 32(7), 2195–2197 (2012).
   PubMed Web of Science ®Google Scholar
• Chatzikyriakidou A , GeorgiouI, VoulgariPV et al. The role of tumor necrosis factor (TNF)-α and TNF receptor polymorphisms in susceptibility to ankylosing spondylitis. Clin. Exp. Rheumatol. 27(4), 645–648 (2009).
   PubMed Web of Science ®Google Scholar
• Li B , WangP, LiH. The association between TNF-α promoter polymorphisms and ankylosing spondylitis: a meta-analysis. Clin. Rheumatol.29(9), 983–990 (2010).
   PubMed Web of Science ®Google Scholar
• Poddubnyy DA , Märker-HermannE, Kaluza-SchillingW et al. Relation of HLA-B27, tumor necrosis factor-α promoter gene polymorphisms, and T cell cytokine production in ankylosing spondylitis – a comprehensive genotype-phenotype analysis from an observational cohort. J. Rheumatol. 38(11), 2436–2441 (2011).
   PubMed Web of Science ®Google Scholar
• Zinovieva E , BourgainC, KadiA et al. Comprehensive linkage and association analyses identify haplotype, near to the TNFSF15 gene, significantly associated with spondyloarthritis. PLoS Genet. 5(6), e1000528 (2009).
   PubMed Web of Science ®Google Scholar
• Lu MC , YangKL, TungCH et al. Higher LPS-stimulated TNF-α mRNA levels in peripheral blood mononuclear cells from Chinese ankylosing spondylitis patients with -308G/A polymorphism in promoter region of tumor necrosis factor: association with distinct A33/B58/Cw10 haplotypes. Rheumatol. Int. 29(2), 189–195 (2008).
   PubMed Web of Science ®Google Scholar
• Brown MA . Re: Zhu et al. “A novel gene variation of TNF α associated with ankylosing spondylitis: a reconfirmed study”. Ann. Rheum. Dis.67(3), 434; discussion 434–436 (2008).
   PubMedGoogle Scholar
• Nicknam MH , MahmoudiM, AmirzargarAA et al. HLA-B27 subtypes and tumor necrosis factor α promoter region polymorphism in Iranian patients with ankylosing spondylitis. Eur. Cytokine Netw. 20(1), 17–20 (2009).
   PubMed Web of Science ®Google Scholar
• Shiau MY , LoMK, ChangCP et al. Association of tumour necrosis factor α promoter polymorphisms with ankylosing spondylitis in Taiwan. Ann. Rheum. Dis. 66(4), 562–563 (2007).
   PubMed Web of Science ®Google Scholar
• Vargas-Alarcón G , Casasola-VargasJ, Rodríguez-PérezJM et al. Tumor necrosis factor-αpromoter polymorphisms in Mexican patients with spondyloarthritis. Hum. Immunol. 67(10), 826–832 (2006).
   PubMed Web of Science ®Google Scholar
• Davidson SI , LiuY, DanoyPA et al. Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese. Ann. Rheum. Dis. 70(2), 289–292 (2011).
   PubMed Web of Science ®Google Scholar
• Vermeire S , MonsuurF, GroenenP et al. Response to anti-TNFα treatment is associated with the TNFα-308*1 allele. Gastroenterology 118(4), A654 (2000).
   PubMed Web of Science ®Google Scholar
• Louis E , VermeireS, RutgeertsP et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand. J. Gastroenterol. 37(7), 818–824 (2002).
   PubMed Web of Science ®Google Scholar
• Seitz M , WirthmüllerU, MöllerB et al. The -308 tumour necrosis factor-α gene polymorphism predicts therapeutic response to TNFα-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxf.) 46(1), 93–96 (2007).
   PubMed Web of Science ®Google Scholar
• Duricova D , PedersenN, LenicekM et al. Infliximab dependency in children with Crohn‘s disease. Aliment Pharmacol. Ther. 29(7), 792–799 (2009).
   PubMed Web of Science ®Google Scholar
• Tong Q , ZhaoDB, BajracharyaP et al. TNF-α -857 and -1031 polymorphisms predict good therapeutic response to TNF-α blockers in Chinese Han patients with ankylosing spondylitis. Pharmacogenomics 13(13), 1459–1467 (2012).
   PubMed Web of Science ®Google Scholar
• Vasilopoulos Y , ManolikaM, ZafiriouE et al. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol. Diagn. Ther. 16(1), 29–34 (2012).
   PubMed Web of Science ®Google Scholar
• Egger M , SmithGD, PhillipsAN. Meta-analysis: principles and procedures. BMJ315, 1533–1537 (1997).
   PubMed Web of Science ®Google Scholar
• Zeggini E , IoannidisJPA. Meta-analysis in genome-wide association studies. Pharmacogenomics10(2), 191–201 (2009).
   PubMed Web of Science ®Google Scholar
• Lee YH , JiJD, BaeSC et al. Associations between tumor necrosis factor-α (TNF-α) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-α blockers in rheumatoid arthritis: a meta-analysis update. J. Rheumatol. 37(4), 740–746 (2010).
   PubMed Web of Science ®Google Scholar
• Pavy S , ToonenEJ, Miceli-RichardC et al. Tumour necrosis factor α -308G->A polymorphism is not associated with response to TNFα blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann. Rheum. Dis. 69(6), 1022–1028 (2010).
   PubMed Web of Science ®Google Scholar
• Zeng Z , DuanZ, ZhangT et al. Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis. Mod. Rheumatol. 23(3), 489–495 (2013).
   PubMed Web of Science ®Google Scholar
• Huang F , ZhangF, ZhengY et al. A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis. Chin. J. Intern. Med. 50(12), 1043–1047 (2011).
   PubMedGoogle Scholar

▪ Websites

• Paget S. Colitis and arthritis: what‘s the connection? Experts and Viewpoints. Medscape Rheumatology (2013). www.medscape.com/viewarticle/807165_2
   Google Scholar
• RevMan 5 download and installation. http://ims.cochrane.org/revman/download
   Google Scholar